ABTB2 Regulatory Variant as Predictor of Epirubicin-Based Neoadjuvant Chemotherapy in Luminal A Breast Cancer

Background: Epirubicin combined with docetaxel is the cornerstone of neoadjuvant chemotherapy (NAC) for breast cancer. The efficacy of NAC for luminal A breast cancer patients is very limited, and single nucleotide polymorphism is one of the most important factors that influences the efficacy. Our s...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Yajie, Hu, Nanlin, Ma, Li, Li, Wentong, Cheng, Xiang, Zhang, Yi, Zhu, Ying, Yang, Yang, Peng, Xiating, Zou, Danyi, Tian, Jianbo, Yang, Lan, Mei, Shufang, Wang, Xiaoyang, Lo, Chun-han, Chang, Jiang, Hou, Tieying, Zhang, Hong, Xu, Binghe, Zhong, Rong, Yuan, Peng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545368/
https://www.ncbi.nlm.nih.gov/pubmed/33102228
http://dx.doi.org/10.3389/fonc.2020.571517

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7545368/
https://www.ncbi.nlm.nih.gov/pubmed/33102228
http://dx.doi.org/10.3389/fonc.2020.571517

Ejemplares similares